(+)-schisandrin B multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC46A3 mRNA] CTD PMID:31150632 (-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1606669 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC46A3 mRNA CTD PMID:22079256 1,1-dichloroethene decreases expression ISO RGD:1332502 6480464 vinylidene chloride results in decreased expression of SLC46A3 mRNA CTD PMID:26682919 1,2-dimethylhydrazine decreases expression ISO RGD:1332502 6480464 1, 2-Dimethylhydrazine results in decreased expression of SLC46A3 mRNA CTD PMID:22206623 17beta-estradiol multiple interactions ISO RGD:1606669 6480464 [Estradiol co-treated with TGFB1 protein] results in increased expression of SLC46A3 mRNA CTD PMID:30165855 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1332502 6480464 [Tetrachlorodibenzodioxin binds to AHR protein] which results in increased expression of SLC46A3 mRNA, [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC46A3 mRNA CTD PMID:16214954 , PMID:25975270 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1332502 6480464 Tetrachlorodibenzodioxin results in increased expression of SLC46A3 mRNA CTD PMID:19770486 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1332502 6480464 Tetrachlorodibenzodioxin affects the expression of SLC46A3 mRNA CTD PMID:20702594 , PMID:26377647 2,3,7,8-Tetrachlorodibenzofuran affects expression ISO RGD:1332502 6480464 2 more ... CTD PMID:20702594 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1606669 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SLC46A3 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol decreases expression ISO RGD:1332502 6480464 bis(4-hydroxyphenyl)sulfone results in decreased expression of SLC46A3 mRNA CTD PMID:33297965 7,12-dimethyltetraphene increases expression ISO RGD:1332502 6480464 9 more ... CTD PMID:32553695 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of SLC46A3 mRNA CTD PMID:31881176 acrylamide affects expression EXP 6480464 Acrylamide affects the expression of SLC46A3 mRNA CTD PMID:28959563 aflatoxin B1 decreases expression ISO RGD:1606669 6480464 Aflatoxin B1 results in decreased expression of SLC46A3 mRNA CTD PMID:27153756 aristolochic acid A increases expression ISO RGD:1606669 6480464 aristolochic acid I results in increased expression of SLC46A3 mRNA CTD PMID:33212167 atrazine affects methylation EXP 6480464 Atrazine affects the methylation of SLC46A3 gene CTD PMID:28931070 benzo[a]pyrene increases expression ISO RGD:1332502 6480464 Benzo(a)pyrene metabolite results in increased expression of SLC46A3 mRNA, Benzo(a)pyrene results in increased expression of SLC46A3 mRNA CTD PMID:19770486 more ... benzo[a]pyrene decreases expression ISO RGD:1606669 6480464 Benzo(a)pyrene results in decreased expression of SLC46A3 mRNA CTD PMID:32234424 benzo[a]pyrene affects methylation ISO RGD:1606669 6480464 Benzo(a)pyrene affects the methylation of SLC46A3 promoter CTD PMID:27901495 benzo[a]pyrene multiple interactions ISO RGD:1332502 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA, [Benzo(a)pyrene results in increased activity of AHR protein] which results in increased expression of SLC46A3 mRNA CTD PMID:27858113 , PMID:32553695 benzo[b]fluoranthene multiple interactions ISO RGD:1332502 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA CTD PMID:27858113 Benzo[k]fluoranthene increases expression ISO RGD:1332502 6480464 benzo(k)fluoranthene results in increased expression of SLC46A3 mRNA CTD PMID:26377693 bis(2-chloroethyl) sulfide increases expression ISO RGD:1606669 6480464 Mustard Gas results in increased expression of SLC46A3 mRNA CTD PMID:25102026 bis(2-ethylhexyl) phthalate increases expression ISO RGD:1606669 6480464 Diethylhexyl Phthalate results in increased expression of SLC46A3 mRNA CTD PMID:31163220 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of SLC46A3 mRNA CTD PMID:30816183 , PMID:32528016 bisphenol A decreases methylation ISO RGD:1606669 6480464 bisphenol A results in decreased methylation of SLC46A3 gene CTD PMID:31601247 bisphenol A increases expression ISO RGD:1332502 6480464 bisphenol A results in increased expression of SLC46A3 mRNA CTD PMID:34585602 bisphenol F multiple interactions ISO RGD:1606669 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SLC46A3 mRNA CTD PMID:28628672 carbon nanotube decreases expression ISO RGD:1332502 6480464 Nanotubes more ... CTD PMID:25554681 , PMID:25620056 cefaloridine increases expression EXP 6480464 Cephaloridine results in increased expression of SLC46A3 mRNA CTD PMID:18500788 chlorpyrifos increases expression ISO RGD:1332502 6480464 Chlorpyrifos results in increased expression of SLC46A3 mRNA CTD PMID:32715474 chromium(6+) decreases expression ISO RGD:1606669 6480464 chromium hexavalent ion results in decreased expression of SLC46A3 mRNA CTD PMID:30690063 chrysene multiple interactions ISO RGD:1332502 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA CTD PMID:27858113 cisplatin multiple interactions ISO RGD:1606669 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of SLC46A3 mRNA CTD PMID:27392435 clofibrate decreases expression ISO RGD:1332502 6480464 Clofibrate results in decreased expression of SLC46A3 mRNA CTD PMID:23811191 cyclosporin A decreases expression ISO RGD:1606669 6480464 Cyclosporine results in decreased expression of SLC46A3 mRNA CTD PMID:20106945 dexamethasone multiple interactions ISO RGD:1606669 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SLC46A3 mRNA CTD PMID:28628672 dichloroacetic acid decreases expression ISO RGD:1332502 6480464 Dichloroacetic Acid results in decreased expression of SLC46A3 mRNA CTD PMID:28962523 diclofenac decreases expression ISO RGD:1332502 6480464 Diclofenac results in decreased expression of SLC46A3 mRNA CTD PMID:35537566 dioxygen increases expression ISO RGD:1606669 6480464 Oxygen deficiency results in increased expression of SLC46A3 mRNA CTD PMID:26516004 dorsomorphin multiple interactions ISO RGD:1606669 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1606669 6480464 Doxorubicin results in decreased expression of SLC46A3 mRNA CTD PMID:29803840 entinostat increases expression ISO RGD:1606669 6480464 entinostat results in increased expression of SLC46A3 mRNA CTD PMID:27188386 epoxiconazole affects expression ISO RGD:1332502 6480464 epoxiconazole affects the expression of SLC46A3 mRNA CTD PMID:35436446 ferric oxide decreases expression ISO RGD:1332502 6480464 ferric oxide analog results in decreased expression of SLC46A3 mRNA CTD PMID:25086211 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of SLC46A3 mRNA CTD PMID:33387578 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of SLC46A3 mRNA CTD PMID:24136188 indometacin multiple interactions ISO RGD:1606669 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SLC46A3 mRNA CTD PMID:28628672 isotretinoin decreases expression ISO RGD:1606669 6480464 Isotretinoin results in decreased expression of SLC46A3 mRNA CTD PMID:20436886 lipopolysaccharide multiple interactions ISO RGD:1606669 6480464 [S-(1, 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of SLC46A3 mRNA CTD PMID:35811015 lipopolysaccharide decreases expression ISO RGD:1606669 6480464 Lipopolysaccharides results in decreased expression of SLC46A3 mRNA CTD PMID:35811015 metformin decreases expression EXP 6480464 Metformin results in decreased expression of SLC46A3 mRNA CTD PMID:31324951 Muraglitazar decreases expression EXP 6480464 muraglitazar results in decreased expression of SLC46A3 mRNA CTD PMID:21515302 nickel sulfate increases expression ISO RGD:1606669 6480464 nickel sulfate results in increased expression of SLC46A3 mRNA CTD PMID:22714537 oxaliplatin decreases expression EXP 6480464 oxaliplatin results in decreased expression of SLC46A3 mRNA CTD PMID:25729387 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SLC46A3 mRNA CTD PMID:25729387 paracetamol affects expression ISO RGD:1332502 6480464 Acetaminophen affects the expression of SLC46A3 mRNA CTD PMID:17562736 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of SLC46A3 mRNA CTD PMID:33387578 paracetamol decreases expression ISO RGD:1606669 6480464 Acetaminophen results in decreased expression of SLC46A3 mRNA CTD PMID:29067470 perfluorononanoic acid decreases expression ISO RGD:1606669 6480464 perfluoro-n-nonanoic acid results in decreased expression of SLC46A3 mRNA CTD PMID:32588087 phenylmercury acetate increases expression ISO RGD:1606669 6480464 Phenylmercuric Acetate results in increased expression of SLC46A3 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1606669 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC46A3 mRNA CTD PMID:27188386 pirinixic acid multiple interactions ISO RGD:1332502 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of SLC46A3 mRNA CTD PMID:19710929 pirinixic acid decreases expression ISO RGD:1332502 6480464 pirinixic acid results in decreased expression of SLC46A3 mRNA CTD PMID:23811191 potassium chromate multiple interactions ISO RGD:1606669 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC46A3 mRNA CTD PMID:22079256 potassium chromate decreases expression ISO RGD:1606669 6480464 potassium chromate(VI) results in decreased expression of SLC46A3 mRNA CTD PMID:22079256 , PMID:22714537 pregnenolone 16alpha-carbonitrile decreases expression ISO RGD:1332502 6480464 Pregnenolone Carbonitrile results in decreased expression of SLC46A3 mRNA CTD PMID:28903501 progesterone increases expression ISO RGD:1606669 6480464 Progesterone results in increased expression of SLC46A3 mRNA CTD PMID:20864642 resveratrol multiple interactions ISO RGD:1606669 6480464 [Plant Extracts co-treated with Resveratrol] results in increased expression of SLC46A3 mRNA CTD PMID:23557933 rifampicin increases expression ISO RGD:1606669 6480464 Rifampin results in increased expression of SLC46A3 mRNA CTD PMID:27199754 rotenone increases expression EXP 6480464 Rotenone results in increased expression of SLC46A3 mRNA CTD PMID:28374803 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1606669 6480464 [S-(1, 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of SLC46A3 mRNA CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1606669 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silicon dioxide decreases expression ISO RGD:1606669 6480464 Silicon Dioxide analog results in decreased expression of SLC46A3 mRNA CTD PMID:25895662 silicon dioxide increases expression ISO RGD:1606669 6480464 Silicon Dioxide analog results in increased expression of SLC46A3 mRNA, Silicon Dioxide results in increased expression of SLC46A3 mRNA CTD PMID:23806026 , PMID:25351596 Soman decreases expression EXP 6480464 Soman results in decreased expression of SLC46A3 mRNA CTD PMID:19281266 sunitinib decreases expression ISO RGD:1606669 6480464 Sunitinib results in decreased expression of SLC46A3 mRNA CTD PMID:31533062 Tesaglitazar decreases expression EXP 6480464 tesaglitazar results in decreased expression of SLC46A3 mRNA CTD PMID:21515302 tetrachloroethene decreases expression ISO RGD:1332502 6480464 Tetrachloroethylene results in decreased expression of SLC46A3 mRNA CTD PMID:28973375 tetrachloromethane decreases expression ISO RGD:1332502 6480464 Carbon Tetrachloride results in decreased expression of SLC46A3 mRNA CTD PMID:27339419 , PMID:31919559 tetrachloromethane multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC46A3 mRNA] CTD PMID:31150632 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of SLC46A3 mRNA CTD PMID:31150632 tetraphene multiple interactions ISO RGD:1332502 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA CTD PMID:27858113 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of SLC46A3 mRNA CTD PMID:23411599 , PMID:34492290 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of SLC46A3 mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SLC46A3 mRNA CTD PMID:25729387 tremolite asbestos decreases expression ISO RGD:1332502 6480464 tremolite results in decreased expression of SLC46A3 mRNA CTD PMID:29279043 trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of SLC46A3 mRNA CTD PMID:33387578 trichostatin A increases expression ISO RGD:1606669 6480464 trichostatin A results in increased expression of SLC46A3 mRNA CTD PMID:24935251 trovafloxacin decreases expression ISO RGD:1332502 6480464 trovafloxacin results in decreased expression of SLC46A3 mRNA CTD PMID:35537566 valproic acid increases expression ISO RGD:1332502 6480464 Valproic Acid results in increased expression of SLC46A3 mRNA CTD PMID:21427059 valproic acid increases expression ISO RGD:1606669 6480464 Valproic Acid results in increased expression of SLC46A3 mRNA CTD PMID:19101580 more ... valproic acid multiple interactions ISO RGD:1606669 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC46A3 mRNA CTD PMID:27188386 valproic acid affects expression ISO RGD:1606669 6480464 Valproic Acid affects the expression of SLC46A3 mRNA CTD PMID:25979313 vinclozolin decreases expression EXP 6480464 vinclozolin results in decreased expression of SLC46A3 mRNA CTD PMID:23034163 zoledronic acid increases expression ISO RGD:1606669 6480464 zoledronic acid results in increased expression of SLC46A3 mRNA CTD PMID:24714768